Background: Recent studies of HIV pre-exposure prophylaxis (PrEP) in HIV-negative individuals revealed heterogeneous estimates of efficacy from 0% to 77%. Efficacy estimates in randomized clinical trials presume adherence to the intervention. Nonadherence biases efficacy estimates to the null and differences in adherence between studies will lead to differing efficacy estimates. Antiretroviral drug level data obtained during PrEP studies suggest that the heterogeneity in PrEP trial efficacy estimates can be explained by differences in adherence amongst the studies. This presentation will review the impact of nonadherence on efficacy estimates, and the approaches to measure adherence.
Conclusions: The presentation will conclude with post-hoc analyses that suggest that the level of protection against HIV transmission conferred by PrEP in HIV-negative individuals is comparable to the level of protection conferred by antiretroviral therapy in HIV-positive individuals.